In vitro determination of metabolic stability is routinely used to assess the overall metabolic liability of compounds and for prioritization for in vivo studies. If in vitro metabolic stability data could be used to reliably predict in vivo clearance (CL), it would add significant value in the selection of compounds for in vivo pharmacokinetic and pharmacology studies. We have evaluated the utility of our in vitro metabolic stability screening assay to estimate in vivo CL in the mouse. The in vitro mouse clearances (CL in vitro ) of 146 structurally diverse compounds with metabolic stabilities > 30 %, were compared to mouse in vivo CL data. Approximately 45 % of the compounds showed agreement between in vivo CL and predicted CL in vitro within a 2-fold error criteria. The correlation appeared worse when correction for the extent of incorporation of plasma protein binding or both plasma and S9 bindings (i.e. ~14 % and~ 28 % agreement, respectively). Classification of the compounds into three groups based on in vivo CL (<30 mL/min/kg, 30-70 mL/min/kg, and >70 mL/min/kg) did not show any improvement between in vivo CL and predicted CL in vitro . The percentage of compounds falling within the 2-fold error criteria for low CL, moderate CL and high CL groups were 54, 31 and 24 %, respectively. In conclusion, our analysis suggests that in vitro metabolic stability data, as routinely obtained in early ADME screening protocols, does not demonstrate a strong correlation with or predictivity for, absolute in vivo CL in the mouse.
INTRODUCTION
Drug discovery and development is both time consuming and expensive. A study by Adams and Brantner reported that cost of new drug development can vary from 500 million dollars to more than 2,000 million dollars, depending on the clinical indication, manufacturing, etc [1] . Therefore, to raise the efficiency, and reduce the attrition rate of the drug discovery and development process, a more cost-effective industrial practice is becoming increasingly critical. Determination of the metabolic stability of compounds using in vitro hepatic systems (e.g., S-9 fraction), is now common place in the pharmaceutical and biotechnology industries [2] .
It has been suggested that determination of intrinsic CL (CL int ) using these in vitro hepatic systems, provides a measure of in vivo CL [3, 4] . For example, several studies have reported a good correlation between predicted CL in vitro and in vivo CL using hepatocytes and microsomes [3] [4] [5] . However, in contrast, a number of studies have also suggested problems with this approach. For example, Iwatsubo et al. (1997) reported a poor correlation between in vivo CL and in vitro CL int with a number of compounds tested in human liver microsomes [6] . Andersson et al. reported 3 out of 4 compounds with poor predictions of hepatic clearance using human microsomes [7] . Thus, the robustness, accuracy and *Address correspondence to this author at the Drug Metabolism, Pharmacokinetics, Toxicology and Pathology, Lexicon Pharmaceutical Inc., The Woodlands, Texas, USA; Tel: (281) 863 3267; E-mail: ssarawek@yahoo.com precision of using metabolic stability data to predict in vivo CL remain the subject of significant interest.
High throughput S-9 metabolic stability determination is routinely used within the Pharmaceutical and Biotechnology Industries as a means to identify potential metabolic liabilities at an early stage. The potential of this assay to efficiently investigate the metabolic liability of large numbers of compounds provides significant value in compound prioritization and structure-activity relationships (SAR) for lead identification and optimization. In addition, if this in vitro data were capable of reliably estimating potential in vivo CL over a wide range of chemical structures, it would also be of significant value in the prioritization of compounds for the more time consuming and expensive in vivo pharmacokinetic (PK), pharmacodynamic (PD) and toxicology studies. However, an essential requirement is that the assay and data have relevance to, and robustness, to estimate in vivo CL. In this manuscript, we report on our studies with 146 compounds, in which we have investigated the reliability of the in vitro metabolic stability assay to assess in vivo PK performance, as determined by in vivo CL.
MATERIALS AND METHODS

Materials
All reagents used were of standard laboratory reagent grade or better. The 146 structurally diverse test compounds with metabolic stability greater than 30 % were obtained from Lexicon Pharmaceutical Company over the five years. Mouse liver S9 was obtained from Xenotech (Lenexa, KS). C57BL/6 albino male mice were bred by Lexicon Pharmaceutical Company.
Metabolic Stability Assay
The in vitro metabolic stability assay was performed as previously described [8] . Briefly, in one time point study, 146 test compounds at 10 M is mixed with reaction mixture containing 0.45 mg/mL mouse liver S9 fraction, 3.3 mM glucose-6-phosphate/magnesium (Sigma Chemicals St. Louis MO), 0.4 U/mL glucose-6-phosphate dehydrogenase (Sigma Chemicals St. Louis MO). The reaction was initiated by adding 1 mM NADP + (Sigma Chemicals St. Louis MO). After 60 min incubation at 37 o C, the reaction was terminated by adding equal volume of acetonitrile containing 0.5 M verapamil (Sigma Chemicals St. Louis MO) as an internal standard. After protein precipitation, the supernatant was analyzed by LC/MS/MS. In multiple time points study, 27 compounds were selected from 146 compounds and tested at 1 M. Reaction was terminated at 0, 10, 30, and 60 min respectively. Beside time point studies, substrate concentration study was performed using one time point method. 35 compounds were selected from 146 compounds and tested at 1 M and 10 M. The % remaining was calculated by comparing the amount of compounds at 60-min incubation or other time points with the amounts of compounds at time 0 min. The half life (t 1/2 ) was obtained by linear regression of % remaining over 60-min or multiple time points. The precision of the experiment and sample analysis in our laboratory is reflected in inter-day comparisons with midazolam (Sigma Chemicals St. Louis MO) as a positive control, which exhibited a stability of 48.4% remaining, (n = 175, SD = ± 4.83 %, % CV = ± 9.98 %).
Plasma Protein Binding and S-9 Binding
Equilibrium dialysis assay was used to measure plasma protein binding and S-9 binding. 29 compounds were selected from 146 compounds for S9 binding study. Tested compounds (10 M, v/v) were mixed with mouse liver S9 (0.5 mg/mL). The mixtures were subjected to equilibrium dialysis versus phosphate buffer saline (PBS) at 37 o C using HT Dialysis 96 well plate (HT Dialysis LLC, Gales Ferry, CT). Dialysis membranes, with molecular mass cutoff of 12 to 14 K (HT Dialysis LLC, Gales Ferry, CT), were used and the plates were incubated at 37 o C for 4 h. Dialysis experiments were done in duplicate. Once the dialysis period was completed, the S-9 and buffer samples were removed and analyzed by HPLC/MS/MS. Plasma protein bindings of 146 compounds were conducted with the same method as the S-9 binding study.
LogP and Polar Surface Area (PSA)
LogP and PSA were calculated using Scitegic Pipeline Pilot Version 7.0.1.
In vivo Animal Studies
Pharmacokinetics Studies
All mouse experimental procedures were reviewed and approved by the Lexicon Institutional Animal Care and Use Committee (IACUC). Generally, 8-12-week-old C57BL/6 (albino) male mice were used for all pharmacokinetic studies. Animals were housed in micro isolator cages in a temperature and light/dark cycle-controlled environment with access to standard chow diet and water ad libitum.
Four mice were used in each study. Compounds were dissolved in 0.1 % Tween 80 (Sigma Chemicals St. Louis MO) or other vehicles. Mice received a single intravenous dose of 1 mg/kg. Blood samples were collected from either retro-orbitally or from the saphenous vein using EDTA tubes at 0.08, 0.25, 0.5, 1, 2, 4, 6 and 24 h. Plasma was separated by centrifugation at 5000 rpm for 5 min and stored at -20 o C until analysis. Samples were analyzed by LC/MS/MS.
Sample Analysis by LC/MS
The concentration of each compound in the blood plasma from the PK studies was determined by LC/MS/MS. Prior to analysis, the plasma samples were protein precipitated with ten volumes of acetonitrile:water (80:20) containing 1 ug/mL verapamil (Sigma Chemicals St. Louis MO.) as an internal standard. Upon addition of the acetonitrile/water mixture, the plasma was vortexed for 3 minutes and centrifuged for 10 minutes at 14000 rpm with a Beckman Coulter Micro II centrifuge. Calibration curves of the analytes in blood plasma were prepared over the range 1.3 ng/mL to10,000 ng/mL and were protein precipitated as described above. The calibration curves for the analytes were linear over the range of the measured unknown concentrations. The precison intra-and inter-day of analytes were satisfactory with CV value less than 15%. The accuracy of the assay obtained with quality control samples containing 1.3, 46.3 and 1670 ng/mL analytes were between 85 % and 115 %. The liquid chromatography system consisted of a Thermo Electron MS Pump and a CTC HTS autosampler. The chromatography column was an Agilent SB C8, 2.1 mm x 15 mm, 3.5 m particle size. The mobile phases used in the gradient chromatography methods were: A; water with 0.1 % formic acid: B; acetonitrile with 0.1 % formic acid. The gradient had the following time profile: 0 minutes, 95 % A; 0.5 minutes, 95 % A; 1.0 minutes, 5.0 % A; 2 minutes, 5.0 % A; 2.1 minutes 95% A; 2.5 minutes, 95% A. The chromatographic flow rate was 0.5 mL/minute and an injection volume was 10 μL. Mass spectrometry was performed with a Thermo Electron TSQ Quantum Ultra AM or an Applied Biosystems 3000 mass spectrometer. The analyte and internal standard peaks were monitored with single reaction monitoring mode (SRM). Positive mode electrospray ionization was used for most compounds; however, negative mode electrospray and negative mode atomospheric pressure ionization were used for some of the compounds in this study.
The analytical method to determine the levels of compound in the metabolic stability and protein binding studies has similar extraction and chromatography methods to those used for plasma analysis in the PK studies. The mass spectrometry methods generally involved single ion monitoring (SIM) with some compounds requiring SRM methods when more signal:noise was necessary. Percentages of prediction were calculated from the plot between the predicted and observed CL in linear scale. On this plot, dot-lines indicated 2-fold error on the perfect clearance prediction, a solid line. Compounds falling inside the 2-fold error were accepted as good predicted compounds.
Calculations of In Vitro
Data Analysis and Statistics
WinNonlin Professional, version 5.0 (Pharsight Corporation, USA) was used to estimate Pharmacokinetic parameters of tested compounds. Clearance (CL) and volume of distribution at the steady state (Vss) were calculated according to non-compartmental methods. Statistics analysis was performed using nonparametric statistic test (GraphPad Prism ® , version 4.0). Spearman coefficient factor r (r) was used to represent correlation.
RESULTS
The physicochemical properties and in vitro and in vivo ADME parameters, including plasma protein binding, metabolic stability using 10 M substrate concentration and mouse in vivo PK data of 146 compounds of diverse chemotypes are summarized in Table 2 . PSA values were in the range of 45 to 159. LogP values varied between -1.9 to 6.4. The values of f u, plasma ranged from 0.001 to 1. The metabolic stability of these compounds spanned a wide range from 44.7 to 99.9 % stable. In vivo CL was in the range of 0.79 to 89.00 mL/min/kg and Vss varied between 0.19 to 40.9 L/kg.
The possible relationship between in vivo CL and predicted CL in vitro was examined using both the well-stirred model (model A) and parallel-tube model (model E) are presented in Fig. (1) and Tables 2 and 3 . For all 146 compounds, the percentage of compounds falling inside the 2-fold error was similar for the well-stirred and parallel-tube models, (i.e. 45 %). Using either the well-stirred model or parallel-tube model, approximately 27 % and 29% of the compounds were over and under predicted, respectively. A nonparametric statistic test was used to estimate the correlation between in vivo CL and predicted CL in vitro due to the variability in the data. Spearman r was 0.26 for both the well-stirred and parallel tube models. These results indicated no significant correlation between predicted CL in vitro and in vivo CL. Incorporation of the plasma unbound fraction (model B and model F) did not improve the relationship, with both models showing approximately 14 % agreement between in vivo CL and pre-dicted CL in vitro . Spearman r for both models was 0.04 ( Table 2 and Table 3 
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Well stirred model with free fraction in plasma
Well stirred model with free fraction in plasma and free fraction in S9
Well stirred model with Vss and LogP E.
Parallel tube model
Parallel tube model with free fraction in plasma
Note: f u, plasma is the free fraction in plasma, fu, S9 is the free fraction in S9, Vss is the volume distribution at the steady state and Qh is the hepatic blood flow of 90 mL/min/kg. Table 4 ). The results also showed that calculation of t 1/2 using either single or multiple time points produced comparable estimates of predicted CL in vitro (Fig. 3) . To further analyze the data, a binary classification was applied to 146 compounds. The classifications were based on the extent of metabolic stability (i.e moderate 30-70% and high > 70%) as shown in Table 5 . Compounds with in vitro metabolic stability < 30% were not included in this analysis, since they are rarely progressed to in vivo PK studies because of the high degree of metabolism and therefore have limited PK data available. The plots between in vivo CL and predicted CL in vitro calculated from well stirred model (model A) are presented in Fig. (4) . For 27 compounds, with moderate metabolic stability (30%-70% remaining), there was little apparent correlation between in vivo CL and predicted CL in vitro .
The percentage of agreement and Spearman r were ~56% and -0.39, respectively. A similar finding was observed for the 119 compounds with high metabolic stability (>70% remaining). The percentage of agreement and Spearman r were ~43% and 0.17, respectively.
Incorporation of the extent of binding to the mouse liver S-9 was determined for 29 compounds. The extent of S9 binding ranged from 6.5 % to 97.3%. Well stirred model with plasma and S9 binding (Model C) was used to calculate predicted CL in vitro . The result showed that correction of the CL in vitro for the extent of S9 binding did not improve the correlation. In addition, correction for both plasma and S-9 binding together also failed to improve the relationship between in vivo CL and predicted CL in vitro (Fig. 5) . The percentage of compounds falling inside the 2 fold error and Spearman r were 28% and 0.06, respectively ( Table 6 ).
In general, over predicted compounds had lower Vss (1.35 ± 1.35 L/kg), lower in vivo CL (6.88 ± 4.76 mL/min/kg), lower plasma protein binding (74.77% ± 30.61%), lower PSA (90.46 ± 33.48) and had high metabolic stability (i.e. % remaining 76.5 % ± 14.6 %) compared with well predicted and under predicted compounds ( Table 7) . Inclusion of Vss and logP into the well-stirred model (model D) improved the agreement between predicted CL in vitro and in vivo CL to~ 59 % for over predicted compounds and to ~ 19 % for under predicted compounds, whereas, inclusion of Vss and logP worsened the agreement by 57 % for well predicted compounds (Fig. 6) . Under predicted compounds were generally metabolically stable (~ 89 % remaining) and had clearance values of ~ 50 mL/kg/min.
In an attempt to improve the relationship between predicted CL in vitro and in vivo CL, compounds were classified into 3 groups based on in vivo CL values (low: < 30 mL/min/kg , medium: 30-70 mL/min/kg and high: > 70 mL/min/kg) [9, 10] . The percentage agreement for compounds with CL < 30 mL/min/kg, CL values of 30-70 mL/min/kg, and CL > 70 mL/min/kg was 54 %, 31 % and 24 % respectively. Spearman r values for compounds with low, medium and high CL were 0.011, -0.039 and -0.512, respectively. These results showed that there was poor correlation between in vivo CL and predicted CL in vitro for all groups, although the low CL group showed a slightly better prediction of CL compared with moderate and high CL groups. Most of compounds in the high CL group showed under prediction of CL (Fig. 7, Table 8 ).
DISCUSSION
Earlier published studies have suggested that intrinsic CL obtained from in vitro metabolic studies can be used to predict in vivo CL [8, 11, 12] . The good correlation appears to have been observed generally with extensively metabolized compounds for which hepatic clearance was the major clearance mechanism. In general industry practice, compounds showing high metabolic instability (<30 % remaining) are usually not advanced into in vivo study. We have therefore examined whether the commonly used high throughput metabolic stability assay can provide a robust and reliable estimation of in vivo CL.
In this study, we have investigated the correlation between in vivo CL and predicted CL in vitro for 146 structurally diverse compounds. The metabolic stability assay used to determine CL in vitro was performed with mouse liver S9 and CL in vitro was calculated using well-stirred or parallel tube [3, 7, 8, 13, 14] .
The inclusion of both plasma protein binding and microsome binding has been suggested to be important in liver models [8, 15] . However, our study showed that including both plasma binding and S9 binding did not improve a correlation between in vivo CL and predicted CL in vitro .
The use of the disappearance method to determine CL int is based on the concept that CL int is close to V max /K m when substrate concentrations are << K m , namely under linear condition. In addition to substrate concentrations, enzyme concentrations and incubation time are also important for linearity. In our study, we have used 10 M substrate concentrations, mouse liver S-9 concentration of 0.45 mg/mL and a 60 min incubation time. This method is commonly used in the industry for the conduct of high throughput metabolic stability studies. Substrate and enzyme concentrations used in previous studies varied between 0.5 M and 1 M substrates and ranged from 0.2 mg to 10 mg microsomal protein/mL, respectively [8, 11, 16] . Although, our substrate concentration was slightly higher than has been used in some other studies, studies in which we have used a substrate concentration of 1 M or with multiple time points showed insignificant improvement in the relationship between in vivo CL and predicted CL in vitro ( Fig. 3 and Table 4 ).
CL in vitro corrected with Vss and LogP (model D) could improve the prediction of CL in vitro for over predicted compound and under predicted compound. But, for well predicted compounds, using Vss and LogP showed poorer prediction of CL than without using Vss and LogP (model A). However, this model requires in vivo Vss data, and thus this approach would not be applicable for early screening approach and defeat the purpose of using in vitro data to predict in vivo CL.
The use of empirical scaling factor (SF) to improve the correlation between in vitro and in vivo data was used in the study of Ito and Houston [12] . The empirical SF was deter- mined by the regression analysis to obtain the best fit between intrinsic CL in vivo and intrinsic CL in vitro. Our study showed that the ratio in vivo CL/ predicted CL in vitro varied from 0.02 to 94. Therefore, a single scaling factor was not applicable to the structural diversity of the compounds used in our study or typically investigated in drug discovery.
The apparent poor agreement in our study between in vivo CL and predicted CL in vitro was similar to the observation of some others using microsomes, hepatocytes and S-9 from humans or rats. prediction of hepatic CL using well-stirred model and CL int calculated from enzyme kinetic measurement. Three out of four compounds showed under, and overestimation of in vivo CL when including and excluding plasma protein binding [7] . Carlile et al. reported poor predicted CL int of some CYP2C9 substrates using human microsomes with the predicted/observed CL int ratios of 0.05-0.31 [17] . Masimiremnwa et al. found no correlation between in vitro half life in rat liver S-9 and measured blood CL in vivo of 48 compounds in the same chemical series [18] . Thus our results appear to be in agreement with the studies that have not shown good agreement between predicted CL in vitro and in vivo CL with a larger number of compounds and various chemotypes.
CONCLUSION
This study was specifically designed to investigate the utility of the high throughput metabolic stability assay to generate an estimate of CL int, in vitro and to estimate in vivo CL. The metabolic stability assay is run in generally high throughput mode over a wide range of chemical diversity and metabolic stability. Therefore if this approach is to have utility in estimating in vivo CL it must have generic applicability, robustness and accuracy in the prediction of in vivo CL. The results of our studies suggest that CL int, in vitro calculated from metabolic stability data obtained using mouse liver S9 could not reliably predict in vivo CL. The data in the literature is inconsistent in regard to the utility of predicting in vivo CL from CL int, in vitro with reports showing both good and poor agreement. It is not readily apparent why these differences appear to exist in the literature in regard to the utility of CL int, in vitro to predict in vivo CL. In our studies it was also not readily obvious why some compounds did appear to correlate with in vivo CL data, and others did not. Certainly, some studies do suggest that inclusion of a scaling factor can improve the correlation [12] . However, it remains unclear whether such scaling factors have generic applicability or are chemotype specific. From our studies with a large number of chemicals and using diverse chemotypes, there does not appear to be a common scaling factor. If such scaling factors are chemotype specific, then their utility would be restrictive and would not meet the criteria for use of high throughput metabolic stability screening data in providing as estimate of in vivo CL. However, overall the results from our studies suggest that in vitro metabolic data from mouse liver S9 does not reliably predict in vivo metabolic CL. It is also not clear from the literature, whether metabolic stability data from other in vitro hepatic systems can be used reliably to predict in vivo CL over a diverse range of chemical entities. In conclusion, the currently employed in vitro high throughput screening approaches for the determination of metabolic stability do not appear to reliably predict in vivo CL.
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